Literature DB >> 15801000

Identification of effective siRNA against K-ras in human pancreatic cancer cell line MiaPaCa-2 by siRNA expression cassette.

Wei Wang1, Chun-You Wang, Ju-Hua Dong, Xiong Chen, Min Zhang, Gang Zhao.   

Abstract

AIM: We shall construct the small interfering RNA (siRNA) expression cassette (SEC) targeting activated K-ras gene sequence, identify more effective siRNA sequence against K-ras gene in human pancreatic cancer cell line MiaPaCa-2 by SEC and reveal the anti-cancer effects of RNA interference (RNAi) and its therapeutic possibilities.
METHODS: Three different sites of SECs were constructed by PCR. K1/siRNA, K2/siRNA and K3/siRNA are located at sites 194, 491 and 327, respectively. They were transfected into MiaPaCa-2 cells by liposome to inhibit the expression of activated K-ras. In the interfering groups of sites 194 and 491, we detected the apoptosis in cells by FACS after they were incubated for 48 h, then we tested the alternation of K-ras gene in MiaPaCa-2 cells by RT-PCR immunofluorescence, respectively.
RESULTS: Introduction of the K1/siRNA and K2/siRNA against K-ras into MiaPaCa-2 cells leads to increased apoptosis, and the number of apoptotic cells is increased compared with control cells. The tests of RT-PCR immunofluorescence show the effects of inhibiting expression of activated K-ras gene by RNA interference in the K1/siRNA and K2/siRNA groups. We also find that the introduction of K3/siRNA has no effect on MiaPaCa-2 cells.
CONCLUSION: K1/siRNA and K2/siRNA can inhibit the expression of activated K-ras but K3/siRNA has no effect, demonstrating that K1/siRNA and K2/siRNA are effective sequences against K-ras gene and K3/siRNA are not. We conclude that specific siRNA against K-ras expression may be a powerful tool to be used therapeutically against human pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15801000      PMCID: PMC4305731          DOI: 10.3748/wjg.v11.i13.2026

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  15 in total

1.  Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells.

Authors:  Patrick J Paddison; Amy A Caudy; Emily Bernstein; Gregory J Hannon; Douglas S Conklin
Journal:  Genes Dev       Date:  2002-04-15       Impact factor: 11.361

Review 2.  Inhibition of virus replication by RNA interference.

Authors:  P C Joost Haasnoot; Daniel Cupac; Ben Berkhout
Journal:  J Biomed Sci       Date:  2003       Impact factor: 8.410

3.  Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects.

Authors:  David A Tuveson; Alice T Shaw; Nicholas A Willis; Daniel P Silver; Erica L Jackson; Sandy Chang; Kim L Mercer; Rebecca Grochow; Hanno Hock; Denise Crowley; Sunil R Hingorani; Tal Zaks; Catrina King; Michael A Jacobetz; Lifu Wang; Roderick T Bronson; Stuart H Orkin; Ronald A DePinho; Tyler Jacks
Journal:  Cancer Cell       Date:  2004-04       Impact factor: 31.743

4.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

5.  Ribonuclease activity and RNA binding of recombinant human Dicer.

Authors:  Patrick Provost; David Dishart; Johanne Doucet; David Frendewey; Bengt Samuelsson; Olof Rådmark
Journal:  EMBO J       Date:  2002-11-01       Impact factor: 11.598

6.  Effective expression of small interfering RNA in human cells.

Authors:  Cynthia P Paul; Paul D Good; Ira Winer; David R Engelke
Journal:  Nat Biotechnol       Date:  2002-05       Impact factor: 54.908

7.  Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells.

Authors:  Nan Sook Lee; Taikoh Dohjima; Gerhard Bauer; Haitang Li; Ming-Jie Li; Ali Ehsani; Paul Salvaterra; John Rossi
Journal:  Nat Biotechnol       Date:  2002-05       Impact factor: 54.908

Review 8.  K-ras mutation: early detection in molecular diagnosis and risk assessment of colorectal, pancreas, and lung cancers--a review.

Authors:  T Minamoto; M Mai; Z Ronai
Journal:  Cancer Detect Prev       Date:  2000

9.  Stable suppression of tumorigenicity by virus-mediated RNA interference.

Authors:  Thijn R Brummelkamp; René Bernards; Reuven Agami
Journal:  Cancer Cell       Date:  2002-09       Impact factor: 31.743

10.  Ki-ras oncogene activation in preinvasive pancreatic cancer.

Authors:  N R Lemoine; S Jain; C M Hughes; S L Staddon; B Maillet; P A Hall; G Klöppel
Journal:  Gastroenterology       Date:  1992-01       Impact factor: 22.682

View more
  4 in total

Review 1.  Vertically integrated translational studies of PDX1 as a therapeutic target for pancreatic cancer via a novel bifunctional RNAi platform.

Authors:  J Wu; S Liu; J Yu; G Zhou; D Rao; C M Jay; P Kumar; R Sanchez; N Templeton; N Senzer; P Maples; J Nemunaitis; F C Brunicardi
Journal:  Cancer Gene Ther       Date:  2014-01-24       Impact factor: 5.987

2.  Modulation of anthracycline-induced cytotoxicity by targeting the prenylated proteome in myeloid leukemia cells.

Authors:  Michael A Morgan; Fredrick O Onono; H Peter Spielmann; Thangaiah Subramanian; Michaela Scherr; Letizia Venturini; Iris Dallmann; Arnold Ganser; Christoph W M Reuter
Journal:  J Mol Med (Berl)       Date:  2011-09-14       Impact factor: 4.599

Review 3.  Pancreatic Cancer: Nucleic Acid Drug Discovery and Targeted Therapy.

Authors:  Hong Dai; Razack Abdullah; Xiaoqiu Wu; Fangfei Li; Yuan Ma; Aiping Lu; Ge Zhang
Journal:  Front Cell Dev Biol       Date:  2022-05-16

Review 4.  Pre-Clinical and Clinical Applications of Small Interfering RNAs (siRNA) and Co-Delivery Systems for Pancreatic Cancer Therapy.

Authors:  Sepideh Mirzaei; Mohammad Hossein Gholami; Hui Li Ang; Farid Hashemi; Ali Zarrabi; Amirhossein Zabolian; Kiavash Hushmandi; Masoud Delfi; Haroon Khan; Milad Ashrafizadeh; Gautam Sethi; Alan Prem Kumar
Journal:  Cells       Date:  2021-11-29       Impact factor: 6.600

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.